5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis

  • STATUS
    Recruiting
  • End date
    Sep 19, 2023
  • participants needed
    630
  • sponsor
    Infectopharm Arzneimittel GmbH
Updated on 19 February 2021

Summary

The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical device) versus placebo and investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is performed in accordance with both the laws in force for clinical trials with medical devices and those with medicinal products.

Details
Condition Actinic keratosis
Treatment Placebo, Solcera, Solaraze
Clinical Study IdentifierNCT04552327
SponsorInfectopharm Arzneimittel GmbH
Last Modified on19 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years and < 90 years
Actinic keratosis grade I (mild) or II (moderate) according to the definition by Olsen with palpable or clinically/dermatoscopically apparent keratosis
Either lesions being well accessible/treatable by the patient or presence of a second person to do the daily applications
Written informed consent by the patient

Exclusion Criteria

Number of initial lesions to be treated 6
Overall size of the area to be treated > 25 cm2
Size (maximum diameter) of single lesion to be treated > 20 mm
Lesions in close proximity to the eyes, eyelids, nostrils, mouth or mucosal tissue
Need for topical treatment of cancerous area
Presence of a relapsing, persistent, indurated, thickened, painful, bleeding, ulcerated and/or rapidly growing lesion
Existing skin cancer (all forms of skin cancer incl. basal-cell carcinoma and squamous cell carcinoma) in the area to be treated in this study
Dermal injuries, skin infection or exfoliative dermatitis in the area to be treated in this study
Other skin diseases in the area to be treated in this study that affect the diagnostic assessment
Pharmacological or physical local therapy of actinic keratosis (or application of the active ingredients used in the pharmacological therapy) in the area to be treated in this study during the last 4 weeks
Primary or secondary immunodeficiency
Treatment with interferons, interferon inducers, immunomodulators or systemic corticosteroids during the last 4 weeks
Treatment with oral isotretinoin during the last 6 months
Intracranial bleeding in the medical history or generally increased primary bleeding tendency
Known intolerance/hypersensitivity to one of the ingredients of the investigational products, especially to diclofenac, parabens or benzyl alcohol as well as to NSAIDs, in particular acetylsalicylic acid
Pregnancy and lactation
Women of child-bearing potential either wishing to become pregnant or without effective contraception
Other serious diseases, which are (according to the investigator's assessment) in conflict with the study participation (i.a. also in view of risk factors for a severe course of a potential COVID-19 disease in case of a SARS-CoV-2 infection)
Obvious unreliability or lack of cooperation
Known addiction to alcohol, medicinal products or drugs
Dependency on the sponsor or an investigator
Participation in a clinical trial during the last 30 days
Previous participation in the present clinical trial
Participation of a family member (in the same household) in the present clinical trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note